FIGURE 1 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers

Expression of AURKA and EGFR in NSCLC. A, EGFR mRNA expression in KRASmut versus EGFRmut NSCLC, from a combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. B, EGFR protein expression in KRASmut versus EGFRmut in LUAD PanCancer study. Expression data are presented as RPPA z-scored values (356 samples). C, AURKA mRNA expression in KRASmut versus EGFRmut NSCLC, in a combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. D,AURKA copy-number changes dependent on mutation status of KRAS, EGFR, and TP53, in a combined set of 411 samples (LUAD PanCancer, OncoSG, and CPTAC studies). E, AURKA mRNA expression in KRASmut versus EGFRmut NSCLC based on TP53 mutation status, in a combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. F, EGFR mRNA expression in KRASmut versus EGFRmut NSCLC based on TP53 mutation status in combined set of 789 samples (LUAD PanCancer, OncoSG, and CPTAC studies). Expression data are presented as RSEM z-scored values. See Materials and Methods for details of data retrieval and analysis.